{"entity":{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","aka":["ASPEN-06"],"tldr":"A phase 2/3 trial testing Evorpacept in gastric & gastro-oesophageal junction cancer, active and no longer recruiting.","summary":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) is a phase 2/3 interventional study registered as NCT05002127, led by ALX Oncology with Eli Lilly and, and active but no longer recruiting on the registry. Official title: A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). Planned enrolment is 127 participants (actual). The study started in 2022-01-15 and primary completion is expected in 2024-05-24. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05002127","url":"https://clinicaltrials.gov/study/NCT05002127"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gastric","gastric-her2-positive"],"sections":[],"technologies":["cd47-blockade"],"targets":[],"drugs":["evorpacept"],"companies":["alx-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05002127","phase":"2/3","setting":"A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)","sponsor":"ALX Oncology","participation":[{"nct":"NCT05002127","source":"https://clinicaltrials.gov/study/NCT05002127","fetchedAt":"2026-10-07T16:53:32.028Z","studySha256":"3c4f8009ac1b4f71f0f93dacf291c277306cdba055fc0b3d8743db281d993b04","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-08-07","leadSponsor":"ALX Oncology Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":127,"enrolmentType":"ACTUAL","siteCount":83,"recruitingSiteCount":0,"countries":["Australia","Belgium","Czechia","France","Italy","Japan","Singapore","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2022-01-15","startedType":"actual","enrolled":127,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/aspen-06/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"}],"technology":[{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/"}],"drug":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/"}],"company":[{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/"}],"term":[{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/"}]}}